<SEC-DOCUMENT>0001213900-25-003165.txt : 20250114
<SEC-HEADER>0001213900-25-003165.hdr.sgml : 20250114
<ACCEPTANCE-DATETIME>20250114083008
ACCESSION NUMBER:		0001213900-25-003165
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20250114
FILED AS OF DATE:		20250114
DATE AS OF CHANGE:		20250114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immuron Ltd
		CENTRAL INDEX KEY:			0001660046
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38104
		FILM NUMBER:		25527828

	BUSINESS ADDRESS:	
		STREET 1:		62 LYGON STREET
		STREET 2:		LEVEL 3
		CITY:			CARLTON, VICTORIA
		STATE:			C3
		ZIP:			3053
		BUSINESS PHONE:		61 03 9824 5254

	MAIL ADDRESS:	
		STREET 1:		62 LYGON STREET
		STREET 2:		LEVEL 3
		CITY:			CARLTON, VICTORIA
		STATE:			C3
		ZIP:			3053
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0227578-6k_immuron.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 UNDER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the Month of January 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File Number: 001-38104</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>IMMURON LIMITED</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name of Registrant)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Level 3, 62 Lygon Street, Carlton South,
Victoria, 3053, Australia</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive office)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F &#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether by furnishing the information contained
in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Yes &#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
&#9746;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If &ldquo;Yes&rdquo; is marked, indicate below the file number assigned
to the registrant in connection with Rule 12g3-2(b): 82-</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>IMMURON LIMITED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXPLANATORY NOTE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Immuron Limited (the &ldquo;Company&rdquo;) published
one announcement (the &ldquo;Public Notice&rdquo;) to the Australian Securities Exchange on January 14, 2025 titled:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Immuron Announces Travelan Clinical Trial Update&rdquo;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 273pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A copy of the Public Notice is attached as an exhibit to this report
on Form 6-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This report on Form 6-K (including the exhibit
hereto) shall not be deemed to be &ldquo;filed&rdquo; for purposes of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange
Act&rdquo;) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be
expressly set forth by specific reference in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: bottom; width: 9%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B> <BR>
<B>Number</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 90%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="ea022757801ex99-1_immuron.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U STYLE="text-decoration: none">Immuron Announces Travelan Clinical Trial Update</U></FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMMURON LIMITED</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 36%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: January 14 2025</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Phillip Hains</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phillip Hains</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Secretary</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">3</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea022757801ex99-1_immuron.htm
<DESCRIPTION>IMMURON ANNOUNCES TRAVELAN CLINICAL TRIAL UPDATE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: center"><B><IMG SRC="ex99-1_001.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Immuron Announces
Travelan<SUP>&reg;</SUP> Clinical Trial Update</B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Highlights:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Travelan<SUP>&reg;</SUP> (IMM-124E) Phase 2 Clinical
Study Report submitted to the FDA</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Travelan<SUP>&reg;</SUP> (IMM-124E) Phase 2 Clinical
Study Statistically Significant Immunology Results</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Travelan<SUP>&reg;</SUP> (IMM-124E) Phase 2 Clinical
Study Statistically Significant Microbiome Responses</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Travelan<SUP>&reg;</SUP> P2TD (n=866) Uniformed Services
University field study randomized 776 subjects</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Melbourne, Australia, January 14, 2025: Immuron
Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that it
has submitted the Clinical Study Report to the U.S. Food and Drug Administration (FDA) for the recently completed Phase 2 study and will
soon request and end of Phase 2 meeting which is a pre-cursor to proceeding to Phase 3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Travelan<SUP>&reg;</SUP> (IMM-124E) Phase 2 Clinical Study</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NCT05933525: A Randomized, Double-blind, Placebo-controlled
Trial Assessing the Efficacy of IMM-124E (Travelan<SUP>&reg;</SUP>) in a Controlled Human Infection Model for Enterotoxigenic Escherichia
Coli (ETEC)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Immunology</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Statistically significant</U></I> lower
levels of IgA and IgG were observed for the subjects who received Travelan<SUP>&reg;</SUP> compared to those who received the placebo, which may
also reflect levels of exposure to ETEC antigen. Travelan<SUP>&reg;</SUP> antibodies target and bind to ETEC antigen in the gastrointestinal tract,
block LPS epitopes and therefore reduce antigen exposure, resulting in lower overall IgA and IgG antibody titers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Clinical data also demonstrated there was a <I><U>statistically
significant</U></I> reduction in the number of colony forming units (CFUs) in the stools of subjects who received Travelan<SUP>&reg;</SUP> (<I><U>p
=0.0121</U></I>), measured 48 hours post challenge, indicating faster clearance of the challenge strain from the GI tract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Microbiome </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Participants in the Travelan<SUP>&reg;</SUP> group have a
more stable gastrointestinal microbiota over the treatment time period when compared with the Placebo group. Alpha diversity, a measurement
of the richness (how many different species) and evenness (abundance or number of different species) revealed that the Travelan group
had improved richness and Shannon diversity results compared to the Placebo group. The data indicated a difference in the richness in
the diversity of certain species rather than just the abundance or number of bacterial species between the two groups.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex99-1_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><IMG SRC="ex99-1_003.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Statistically significant</U></I> differences
were identified between the two treatment groups in the Beta diversity tests (number of species and abundance). The relative abundance
results revealed that the Travelan group had increased levels of beneficial bacteria such as <I>Akkermansia </I>and <I>Faecalibacterium.</I>
The differential abundance results confirmed increases in <I>Agathobaculum, Slackia</I> the <I>Eubacterium eligens group, </I>and <I>the
Eubacterium siraeum group; </I>and decreases in <I>Rumminococcus and Bacteroides</I>. The abundance data indicates a possible link between
the species of bacteria associated with reduced inflammation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This study data implies that Travelan<SUP>&reg;</SUP> appears
to aid in the reduction and clearance over time of pathological ETEC bacteria, by shortening the recovery period after ETEC challenge.
The mechanism indicates there is an increase in the propagation of bacteria associated with decreases in inflammation and repairing the
intestinal lining. Further investigation into this association is required to fully understand the benefits of Travelan<SUP>&reg;</SUP> on the gut
microbiome.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Uniformed Services University field study</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NCT04605783: A Randomized, Double-Blind,
Placebo-Controlled Trial to Evaluate a Dietary Supplement to Maintain Gut Health During Deployment and Travel 776 subjects have been
randomized. We anticipate the last enrollments to occur in March 2025 and follow-up to be completed around June 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This release has been authorised by the directors
of Immuron Limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">- - - END - - -</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%"><P STYLE="margin-top: 0; margin-bottom: 0"><B>COMPANY CONTACT:</B> <B>&nbsp;</B></P>
                           <P STYLE="margin-top: 0; margin-bottom: 0"><B>&nbsp;</B></P>
                           <P STYLE="margin-top: 0; margin-bottom: 0"><B>Steven Lydeamore<BR>
</B> Chief Executive Officer<BR>
 steve@immuron.com</P></TD>
    <TD STYLE="width: 36%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 31%; font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><B>About Immuron</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">Immuron Limited (ASX:
IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal
antibodies for the treatment of infectious diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Travelan<SUP>&reg;</SUP></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">Travelan<SUP>&reg;</SUP> is an
orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers&rsquo; diarrhea, <FONT STYLE="background-color: white">a
digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce</FONT>. Travelan<SUP>&reg;</SUP> is a highly
purified tabletized preparation of hyper immune bovine antibodies and other factors, which when taken with meals bind to diarrhea-causing
bacteria and prevent colonization and the pathology associated with travelers&rsquo; diarrhea. In Australia, Travelan<SUP>&reg;</SUP> is a listed
medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Travelers&rsquo; Diarrhea,
reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan<SUP>&reg;</SUP> is a licensed natural health product
(NPN 80046016) and is indicated to reduce the risk of Travelers&rsquo; Diarrhea. In the U.S., Travelan<SUP>&reg;</SUP> is sold as a dietary supplement
for digestive tract protection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><B>Travelers&rsquo;
diarrhea (TD)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">TD is generally defined
as the passage of &ge; 3 unformed stools per 24 hours plus at least one additional symptom (such as nausea, vomiting, abdominal cramps,
fever, blood/mucus in the stools, or fecal urgency) that develop while abroad or within 10 days of returning from any resource-limited
destinations (Leung et al., 2006). Diarrhea continues to be the most frequent health problem among travelers to destinations in lower-
and middle-income regions (Steffen, 2017). Deployed US military personnel, essentially representing a long-term traveller population,
are particularly affected given their population dynamics and the context in which they seek care and treatment (Connor et al., 2012).
Diarrhea is the leading infectious disease threat to the overall health and preparedness of deployed US armed forces, with diarrheagenic
E. coli, Campylobacter spp., and Shigella spp. among the most commonly reported etiologies (Riddle et al., 2006).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: #FEFEFE"><IMG SRC="ex99-1_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: #FEFEFE"><IMG SRC="ex99-1_003.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>Immuron Platform Technology</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">Immuron&rsquo;s proprietary
technology is based on polyclonal immunoglobulins (IgG) derived from engineered hyper-immune bovine colostrum. Immuron has the capability
of producing highly specific immunoglobulins to any enteric pathogen and our products are orally active. Bovine IgG can withstand the
acidic environment of the stomach and is resistant to proteolysis by the digestive enzymes found in the Gastrointestinal (GI) tract. Bovine
IgG also possesses this unique ability to remain active in the human GI tract delivering its full benefits directly to the bacteria found
there. The underlying nature of Immuron&rsquo;s platform technology enables the development of medicines across a large range of infectious
diseases. The platform can be used to block viruses or bacteria at mucosal surfaces such as the Gastrointestinal tract and neutralize
the toxins they produce.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>IMM-124E (Travelan<SUP>&reg;</SUP>)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">IMM-124E was developed
using Immuron&rsquo;s platform technology. IMM-124E is produced from the colostrum of birthing cattle that have been immunised during
pregnancy with a vaccine containing the outer antigens of multiple human derived ETEC. A total of 13 ETEC strains are used in the vaccine
to produce high levels of antibodies against selected surface antigens from the most common strains of ETEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">The resultant hyperimmune
colostrum IMM-124E from ETEC vaccinated cows contains significant levels of polyclonal antibodies specific for ETEC antigens LPS, CFA-I
and Flagellin (Sears et al., 2017).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">The antibodies produced
in IMM-124E have been found to have a stronger binding and neutralizing activity (than the antibodies of unvaccinated cattle) against
a wide range of LPS antigens including both the variable O-polysaccharide region and the preserved oligosaccharide core &lsquo;R&rsquo;
region of LPS from the 13 serotypes used in the ETEC vaccine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">IMM-124E is manufactured
into a tablet form referred to as Travelan<SUP>&reg;</SUP>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>IMM-529</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">Immuron is developing IMM-529 as an adjunctive
therapy in combination with standard of care antibiotics for the prevention and/or treatment of recurrent Clostridioides difficile infection
(CDI). IMM-529 antibodies targeting Clostridioides difficile (C. diff) may help to clear CDI infection and promote a quicker re-establishment
of normal gut flora, providing an attractive oral preventative for recurrent CDI.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">Immuron is collaborating with Dr. Dena Lyras
and her team at Monash University, Australia to develop vaccines to produce bovine colostrum-derived antibodies. Dairy cows were immunised
to generate hyperimmune bovine colostrum (HBC) that contains antibodies targeting three essential C. diff virulence components. IMM-529
targets Toxin B (TcB), the spores and the surface layer proteins of the vegetative cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">This unique 3-target approach has yielded
promising results in pre-clinical infection and relapse models, including (1) Prevention of primary disease (80% P =0.0052); (2) Protection
of disease recurrence (67%, P &lt;0.01) and (3) Treatment of primary disease (78.6%, P&lt;0.0001; TcB HBC). Importantly IMM-529 antibodies
cross-react with whole cell lysates of many different human strains of C. diff including hypervirulent strains.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">To our knowledge, IMM-529 is, to date, the
only investigational drug that has shown therapeutic potential in all three phases of the disease (Hutton et al., 2017).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: #FEFEFE"><B><IMG SRC="ex99-1_002.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B></B></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>&nbsp;</B></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B><IMG SRC="ex99-1_003.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>References</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">Connor P, Porter CK,
Swierczewski B and Riddle MS. Diarrhea during military deployment: current concepts and future directions. Curr Opin Infect Dis. 25(5):
546-54; 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">Hutton, M.L., Cunningham,
B.A., Mackin, K.E. et al. Bovine antibodies targeting primary and recurrent Clostridium difficile disease are a potent antibiotic alternative.
Sci Rep 7, 3665 (2017). https://doi.org/10.1038/s41598-017-03982-5</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">Leung AK, Robson WL,
Davies HD. Travelers&rsquo; diarrhea. Adv Ther. Jul-Aug; 23(4): 519-27; 2006</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">Riddle MS, Sanders
JW, Putnam SD, and Tribble DR. Incidence, etiology, and impact of diarrhea among long-term travelers&rsquo; (US military and similar populations):
A systematic review. American Journal of Tropical Medicine and Hygiene. 74(5): 891-900; 2006.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">Sears KT, Tennant SM,
Reymann MK, Simon R, Konstantopolos N, Blackwelder WC, Barry EM and Pasetti MF. Bioactive Immune Components of Anti-Diarrheagenic Enterotoxigenic
Escherichia coli Hyperimmune Bovine Colostrum products. Clinical and Vaccine Immunology. 24 (8) 1-14; 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">Steffen R. Epidemiology
of travelers&rsquo; diarrhea. J Travel Med. 24(suppl_1): S2-S5; 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">For more information
visit: https://www.immuron.com.au/ and https://www.travelan.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">Subscribe for Immuron
News: Here</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>FORWARD-LOOKING STATEMENTS:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release may contain &ldquo;forward-looking
statements&rdquo; within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934,
each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development
programs and any other statements that are not historical facts. Forward-looking statements are based on management&rsquo;s current expectations
and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition, and stock
value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth
strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the
results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties
relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key
personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and
intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation
or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in
our expectations or any changes in events, conditions, or circumstances on which any such statement is based, except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">crobiological and Biomedical Laboratories.</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex99-1_002.jpg" ALT=""></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !* 0P# 2(  A$! Q$!_\0
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MH/Q7F\]8=;@0QL<>?",%?JO?\*V?$_Q+LM*(M]+5+VX*@F3=^[3(XZ=36?\
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MI[9:3FXL8+@@ R1JY [9&:\[T[XG32^(197\%M!:!W#S9.5"@G^@KO\ 2_\
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M*OOJG_H0KC/A!_R%M2_ZX+_Z%7:?$/\ Y$F^_P" ?^A"N+^$'_(4U+_K@O\
MZ%3I?[I/^NP5?][A_7<]<KQ?XKC_ (JF$_\ 3NO\S7M%>,?%?_D:(?\ KW7^
M9K/ ?QODR\=_!^:/3_"ASX4TO_KW3^5>,^)SGXA7G_7V/YBO9?"?_(IZ7_U[
MK_*O&O$PQ\0;S_K\'\Q6V$_BS^?YF.+_ (4/E^1[ZGW%^E<[X\4-X*U,'M&#
M_P"/"NB3[B_2N?\ '/\ R)>I_P#7+^HK@I?Q(^J.^K_#EZ,X+X0C_B<WY_Z8
M#_T*O7J\B^$/_(7U#_K@O_H5>NUOCOXS^1A@OX*^9XU\6A_Q4UL?^G5?_0FK
MT7P0<^#-+_ZX_P!37G7Q:_Y&6V_Z]1_Z$U>B^!_^1+TO_KE_4UM7_P!UA_7<
MRH?[S/\ KL>1>)./B)=$_P#/Z/\ T(5[[7@GCJ"2P\<WKL/O2+,ON" :]OTK
M4H-6TNWOK=@T<R!N.Q[CZ@TL8KTZ<EM;_(,([5*D7O?_ #+E>&?$S_D=Y_\
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98Y&&&D8EG/XFM:BBLY2<G=LTC%15DC__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex99-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !C \@# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ***YW7_%_A/PG;M=^*?%'AWPU:HN][G7];TW1K=4Y^=IM1N;:-5X/S%@
M.#S6E*C6KU(TJ%&K7JS=H4J%*K7JS;V4*5&E6J3;Z*%.3\C*M7H8:G.MB:]'
M#T::YJE;$5J.'HP2W<ZU>K0I02L[N=6"7<Z*BOD7QC^WE^R-X'6;^U_CCX0O
MYH"ZFW\+/J'C*5Y$&3$K>%K+5X%8Y&#+-''R,N <U\J^,?\ @L+^S;H>Z+PK
MX;^(_C6X&=DT>EZ3X?TMO0M<ZGJSZG'D]0=%+ =5SQ7W^3^$GB=GW(\KX"XI
MKTZEN6O6RC$Y?AVI6:E]8S5952Y;-/FO)6U/S7//&KPCX;YUG'B/P?AJE._/
MAZ&=X3,\4G&Z<?JV3/.:W-=-<K46WIN?K)17\^7C#_@M-XSN3/%X#^"_AC14
M 9;>[\5>)-3\22,<_)))9Z7:>%TBXP6C^U3\Y ?&#7RAXQ_X*C?M?^+%DCM?
M'FD^#K>4MOM_"'A?0[+:K<%(;W5;;6=7B &,.NI>:IY613S7ZID_T3O%O,N2
M6.P_#_#].5FWF>=T<17@GO?"Y/A\PGS):\KQ"N].9/5?CF>_30\%,IYX9?BN
M)>):L;J*RCAZOAL/-J]K8S.\3EE/E;^TL,[+7E>S_J\) !)(  R2>  .I)[
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M9O;9/$_A?Q?X<9+;QKX+OHE*)?:IX7O6!FELE9;S1[C3=>BACT_4K=C]I5^
M/[.O[+'PZ\#?MX_\%1/V0? \C>%/A9\2_"W[.?[9?@BT\*7$FFW_ ,!_CC\1
MA\2O"GB/Q'X!:S>%/"^I3:_X$TOQKI\%BMM#]GN!I+PRZ+)+:3??_P"Q!^U+
MXC^-OP$\=3?$<61^-W[.WBKQS\(_C''90"SLM6\6_#S[0D'BJTL@ ME9>,--
MAMM5:VCQ!;:@^I6UL%MH(0/YOSKAG#NCC\WR"6(J99AJV2U:N#Q5I8O 8'BB
MBZV2U9U8)1KT8XR&,R3$591A4AC,+A*[4Z&90E2_9,3G]' <18/(<=!4?[8P
M&88_),7&3<,5/)Z=#$9OEM:$M:>-PN#Q-',L.X.=+&8#ZRXJEB<'5IU?RZ_X
M*K?\%B?%GP5\<Z[^S5^RO=Z99>-_#6+'XH?%B]LK76#X5UB>%9'\(^#--O%F
MTV77].@FB;7=;U.WO;?3+N0:996$FH6]S<V_Y5:'\$_^"TOQGT-/C-II_:UU
MBQOK=-7TW5+_ .*E_P"$-5U2S=!=6]WH/A#4?%V@:G+:2HRRV*6>AQ0W"-']
MBBE4KG#_ ."5?P\T7]J#_@I!X8U+XJPQ^);:#4_B-\<-:L-51;VW\0>)=*NI
MM8TM-2BN!)'=VL/B35[359H)UDBG^P)!(CPNRG^[7ITK^@N+.(<E\"8Y'P=P
M[PAPYG6>U,FP.:<29]Q%@88^KBJ^,YDZ%!.E4J0IRG1Q,H1C5HX?#8=8:E##
M5\1+$5Y?A/#629MXP2S?BC/.)\]RK)X9GB\OR+)LDQ<L'2P]+#<K5:M:I"G.
M<(5L/"<I4ZE;$5Y8BI.O2HQHT8_QO_L<_P#!9/\ ::_9Q^*5O\)_VSKOQ3X^
M^'UOK:>'?&,_CO1Y;'XP_"FZ,J6TNIS7$MM9:CK]CIC,D^K:)X@M[C4Y+)9+
MG2M364+;WG]B&DZMIFO:5IFN:+?6VJ:/K.GV>JZ3J5E*D]GJ&FZC;1W=C?6D
MZ$I-;7=K-%/!*A*R12*ZD@BOY</^#BWX,>#M)U#X ?'C2=-M=/\ &7BRZ\3_
M  X\77=M#'"_B#3M%TZRUSPU=Z@44?:;W2!)JFGQ7,H:<V-U;VK.T%I!''^M
MW_!'WQOJWCO_ ()Y?L]WNMW$MW>^'])\1^"4N9G:2673O!WB[7-"T979B2?L
MVD6=C9IDGY+=:^-\4\IX<X@X%X3\5^'<EPW#=?.L?B<EX@R? QC3P']HT%B+
M8K"TH0I4X/VV#KPE.E1H*OAZ^'G6H1Q-"K4K_4>'>99]DO%_$GAQGF:U\]HY
M5@Z&:Y+FF,E*>-^I5G0;P^(J3E4G)>RQ5*483JUG1KT:T:566'K4X4?TQHHH
MK^>3]N"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MADWK%_PC7A"VN;B-&SC,_BJX\2DR*#Q)$L/(!"CG/Y4?:??_ #_WS1]I]_\
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MJ=&I)7A[6-5*;BHRE_;O7X,?L/?"T_L*_P#!4G]O'X%Z_:2:3\/?V\=5T?\
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MD\__ ."1_BV_^*UW_P %0/C79)/%X(^)OQ-UC6_#RR))'%)/>67Q!UEBD;J
MMQ'HFLZ$UTO#H;B)7 ^6OB+]H;]O?]K+_@J[XE3]F#]E+X7:YX0^%FO7EO#X
MELX;HW.JZYIJ7",+_P"*WC&TC70O"'@VS94O;G0;6>87\L:6\U]KDIMM//\
M1#^R_P#LF^&OV-OV09/@GX?N8]9U>V\)^*M<\<^)HK=H6\5>.M;T:9]<U6*%
MOWL=C&T5OI6BVTG[R#1]/L(I09Q*S>1Q9EV(X'X8XACQ=/+,+Q[XDYCPS1H<
M(Y95PU:/"7"F09IALRHRQT,-4JT<%5JSP^ R_+L)&;G3P]"O.4ZLYXFK'PLI
MXP_XC+XEY)G?">%QLO#OPVP?%.(J\58G"8C X3B;BC/<EGD-#+LCAB:5&MB<
MORS /$XG%XF5.,*E2=&\*2>'IU/Y;/\ @@]_RD'TS_LDGQ2_]PE?VZU_$_\
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M=J-Q,TUS=^!]1_L:*8L#\BZ1=V^I^'[5 S%\6.D6K,V-[,H"UYUIW_!-_P"
MUE=1W%WK?Q)U:*.57-E>Z]H,-K/&K ^3<-IWA:QO"' *R/;W=LQ!_=^4P#5^
MG8/Q9KX:DU_9-6G6:][ZGFTZ6%G*UN;V.(P.*JP3ZJ-6;2]V-1I)GGYIEM+.
ME36<8#A[.)T8\M'%9CD]7ZY".ZBZF"S'"0FD[R<.>G2E)M^QIN4K_P GWP]_
M9K_:I_:R\4:)H_Q/N]5AT:[OK=['X;^&;1;*?4)-R-BYTV!4AM8H!N^TZIX@
MN)ETV#S+IYS;13J/Z]_V+/V2?#'[*7PTM] LK'3D\4ZI;VPUNXL%\RUTVUMP
MSVN@:;<.BR26UO+))=:A=D+)JFI2O-*TEO:Z<EO]"?#SX1_#;X46$FG?#[PA
MI/AJ&952YN+6.6YU2]1&+(E_K.H2W>KWT<;EGBCN[V:.)W=HU1G<MZ-7Q/$G
M&&;\3SBL;45'"4Y^TI8*C.K*E[1)QC6KU:TI5L57C"4H0J5N2%&,IQP^'H*=
M2533 Y9A<!&"H4J,/9QG3I0H8:AA,-AZ=1QE4IX7"8:*HT(U90A*M4<L1BL3
M*$'BL975.G3I%%%%?*GHC=B9W;%SG.=HSGUSC.?>E(##! (]" 1^1I:* &JJ
MKG:JKDY.T 9. ,G &3@ 9/8 =J<0",$ @]0>0?PHHH :%5?NJJYZX &?R%.H
MHH 8L:)C8B+@8&U0N!Z# ''M2E5;[RJV.F0#C\Q3J* $554!54*H& J@  >@
M P /I055AA@&'7! (SZ\TM% "!57A5"@G)  '/3/'?  _"AE5@590RG&0P!!
MP<C(.1P0"/0C-+10'ET["!57[JA<]< #/Y4M%% '+^)/ _@KQDL*>+_"'A?Q
M4EOG[.GB3P_I.N+!DDGR5U.TNA%DDD[ O))K2T;0="\.62:;X>T72=!TZ,YC
ML-&TZSTNR0X REK8PP0*< #*Q@X ':M:BM'6K.FJ3JU72B[QI.K5=*+U=XTG
M4=).[;NJ:>KUU=X5*DINJJ5)56K.HJ=-5&NSJ*FJC6BT=1K38*88XR2QC0LV
M"Q**22  "3C)P  ,]  !3Z*S+"BBB@ (!!!&0>"#T(]#7S!XR_8H_9#^(6M2
M>(_&G[-7P5\1:]-*9[G5K_X=^&FOKN9F+-->W$6GQ/>R.Q+.]T9F<DER<U]/
MT5VX',LQRRI*MEN8X_+JTH\DJN7X[&8&K*'\DJF"Q>$G*.K]V4I1U;Y4]3S\
MPRG*LWI1H9ME>69K0A+GA1S/+L!F-*$]N>%+'X+&TX3MISPA"5M')K0XOP+\
M./A]\,-%3PY\-_ _A+P%H$;!UT;P=X>TGPYIID"[1*]GI%I:023;>#-(C2L/
MO.:[3KUHHKFJUJV(JSKXBM5KUJLG.K6KU:M:M4G+5SJ5:U2K5J3;WE4JSD^L
MF=="A0PM&GA\+0H8;#T8*G1P^&HT</0I4X_#"E0H4J%&E!=(4Z5.*Z16MVA$
M7&U%7' PH&!Z# IU%%9FHA56^\H;Z@'^="JJC"J%&2<* !DDDG P,DDDGN22
M:6B@+=>O<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BD) !)(  )))P !R22>  .IKF]5\:>#M"C:76_%GA
MK1XDSODU77=+T^-,==SW=U"JX[Y(Q6E.E5K24*-*K6F]%"C2J59MO9*%*G5D
MV^B46WT1G5K4:$7.O6HT()7<ZU:E1@DMVYUJM*"2ZMS275HZ6BO -<_:N_9A
M\-!SKO[0WP5TTQY\Q)_B;X-,J;>H>&/6'E4CT9 :\BUS_@I!^P[X>W_;_P!H
M_P !7&SK_89UOQ,#_N-X<TC55?/8JQ'OCFOH,'P=Q?F%OJ/"?$^,YMGAN'<]
MJIWVM*.41@__  /SVU/F<=QUP/EE_P"T>-.$<#R_$L7Q1P[0DK;WC/.Y37_@
MN_ET/MRBOR[UO_@L5^PCI!E2V^(_B77WC_@T7X?>+ ).H'ERZQIVD0-DCO*N
M."<#FO&?$'_!=3]D_3=RZ'X(^-/B)UR _P#87A'2K=SV*R77C.6<*?5[5&'/
MRYX/U.#\&/%C'<OU?P\XJM*UI8C*Y8*.O5RQ^*P5EZQ7FD?'X[QY\&,NYOK7
MB=P;>-[QPV;QQ\]-THY=@\?S/R4G?HV?M517\]WB#_@OSX$@$B^%_P!G7Q/J
M9Y$4FN^/]-T4?[+206'A?7,^Z+<#/0..M>*:U_P7U^)\XD'AWX ^ M+8EA$V
ML^)_$6O #^$R+90>'"Q!ZA2H/J,\?4X+Z-7C-C+-\)T\$GUS'/,CPMO6,<=B
MZBMU3A?LF?&X_P"EAX#X&Z7&E3'M7TRSA[B'&7M_+.678*F[]&IVVU1_3Y17
M\BVO_P#!<;]L'56?^RM)^#_AJ,Y"#3/!VL7DJ _=/F:[XHU>,L.Y: J3GY0,
M >)>(O\ @K=^W?X@\Q5^,ZZ%#)G]SX?\$^ ]/* ]H[D^&9KY,#H1= ]R2V"/
MK,%]$;Q2Q'*\5B^$<N3MS>USK$XR4=K^[@,IDI-=E42=M^I\9C_IM>#V&YE@
ML%QKFC5^5T<APN!A+M[V99U"44^[I-KMT/[5J:S*BEW9411EF8A54>I8D #W
M)K^#[Q#^WI^V)XH1X]6_:0^+H23=O32_&NMZ#&=WWL1Z'<Z=&@/3:BJH'  '
M%>(:W\8OBIXF+MXC^)7C[Q 9"3(VN>+O$&KLV>3N?4+ZX8@YY!)![U];@OH9
M\03L\QX[R+#[7C@<GS?&27>TL3B<#!^3<4OD?%8_Z>/#,+K*_#KB+%/7EEF&
M>Y)@8O>S<<)A,PJ+HVN9OINC^_S7?B7\./"REO$WQ \$^'%4;F;7?%>A:0JK
MZDZA?VX ]SQ7A_B']M[]D+PNTB:Q^TA\((Y8<^9;V'C;1M:NAC/2UT2XU"Y;
M.#C9$VX@@9-?P9OJ#[WDDN&#L2SN\Q5F9LY9B2"2><D\GO5.76+),F:_ME(S
MGS+N('W^\^?K7U^"^AGP_#E>9<=YWB']J.!R;*,'%_X98K%XVI%;ZN+?4^(S
M#Z>'$U3F64^'/#^%3OR3S'/<ZQ\EVYH8/!9?3D]M%)+H?VS^(_\ @J]^PGX=
MRI^,[:W(,XCT#P5XYOPS 9VK/)X>MK3GH&:X6,GH^.:\(\1_\%OOV1M)$BZ)
MX?\ B_XID0D*UGX:\.Z9;2#L4EU;Q;;7 !_V[-2!R1U _D!?Q-HD>=^JV0(Y
MP+@.?P"!C51_&GA],_\ $Q#XZ^7%<O\ EB'!_.OL,#]$GPJPO*\7B>+,S:>O
MML[P^#A*W1PR[*H-)]E47DSXC,/IJ^,N+YE@L)P9E,974?J_#V)QTXWVM/-,
MXJ)M=W2MW70_J4\1_P#!>SP) )%\)?L^>)M3)#>5-XA\=:;HH!YVF2VT[P[K
MNX'C<JW:XSPQQ7@OB'_@O)\8KI'7PK\$_AIHK,&"/KNJ>)_$A3/ 8?8;[PNK
MD=1NC"YZJ1D'^=B3Q_H2?=>]E_W+9Q_Z,9.*IR?$;35_U=G?R>F3 G\Y6Q^1
M^E?8X#Z.G@Q@+-<&T<;)6][,\USO'WMUE">98:F_->S2?8^&S'Z47CUF7,GQ
MUB<!&5_=RG)N'\MY4^D9PRK%55:^C]JVN^A^V_B#_@M'^VAK E73M6^'GA8.
M6V-H7@6QG>)2. #XEN_$2L5ZAF!SW!QSX'XA_P""E_[;GB8S?;_V@_&%HLP(
M*:!#H7A<(&SGRF\-:5I+QGG *OE1C;@C-?EO)\25Y\K2I/8RW8'Z)"W_ *%_
MC5*3XD:B<^5IUHGIYDL\N/? \O/YBOL\!X8>&F5\KP/ 7"-"4=IOA_+L145M
MOWF.HX^;?FV]=7J?"9CXM>+6;\RS'Q'XWQ$9-N4%Q-F>%IN^_P"ZR^OEM-+R
M44K:;'VMXB_:2^/GBYY'\4?&OXJ>(/-R'CUGX@>*M2A(/51;WFKS0*O/"K&
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MR(/S:050E\2:-!D3:MI\9'4->0D\>RRD_P"/:OELDMRQ+$]2Q))^I.2?QIN
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MOEG'.,:VY,BP&&4OGB\^37_;T?4_N6HK^!S5/^"L7[<6K;OM7[1OQ&3?G/\
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MC\*^@POT4_"*A9UL-Q-C6M_K'$E>G%^L<)EV'W\I+R/F<7],?QNQ-U0Q?"6
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MK,6/YDFF8'H/RI:*!A1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MB7]I?Q.N1C-MX<\!V1_\DO"MO@^XQCMC)KP3_AA[]M3_ *- _:B_\,!\6/\
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M5SJ6H'K?WG'3_29O_BZ^E?\ AA[]M3_HT#]J+_PP'Q8_^9*C_AA[]M3_ *-
M_:B_\,!\6/\ YDJZ5Q1PO%6CQ/PU%=H\2<.Q7W1S^*_ Y7P?Q;)WEPCQ5)]Y
M<*\32?WRX;D_Q/F<WUZWWKRZ/UN)3_-ZC-S<'K/,?K*Y_P#9J^G/^&'OVU/^
MC0/VHO\ PP'Q8_\ F2H_X8>_;4_Z- _:B_\ # ?%C_YDJ/\ 6GAC_HJ.&_\
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MM1?^& ^+'_S)4?\ ##W[:G_1H'[47_A@/BQ_\R5'^M'"_P#T4_#7_B2<._\
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M#W[:G_1H'[47_A@/BQ_\R5'^M'"__13\-?\ B2<._P#S_#_5#B[_ *)+BO\
M\1;B?_Z&SY=HKZB_X8>_;4_Z- _:B_\ # ?%C_YDJ/\ AA[]M3_HT#]J+_PP
M'Q8_^9*C_6CA?_HI^&O_ !).'?\ Y_A_JAQ=_P!$EQ7_ .(MQ/\ _0V?=_\
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>BBB@ HHHH \J^*/^M^'G_8\S_P#JO_'E%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ex99-1_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  R +<# 2(  A$! Q$!_\0
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M^$?"VG6%M#9V-AX<T.RLK.WC6*WM;2UTRU@MK:") $CA@AC2**- %1%55
MK^2[QGX<T1/^#A32M.33;3['/\:/!_B"2V,*&$ZQ_P *LTGQ0^H"/;M%RVO1
M_P!JF4#>;XM<%C(S,=>$L^X8XXQ?$E#._#_A:AA.%LGS'B?)J>4X2>6UG1R:
M5>V59G7P]2']HX?%06&==UHVE4C5]SD<.;'BS(N)N",+PW7R7C_BBOB^*,WR
M_AG.:F;8N&9456SB-"^:990Q%.:R[$86;Q"H*C*\:<J7O\ZGR]5XQU[_ (+]
M?"'P1/\ M&^+?$GB&Y\-:1;/XE\3>$/LOPBURYT'P_"DE[=7&N> -+TN6[L]
M,L[6,MJ0T^V.I:3:B2XU(V2074\/[+_\$Q/^"@EG^WC\)-:O_$.CZ=X7^,'P
MUO--TGXC:%I,DG]C7\6K0W4FA^+=!M[F>XO;+3-:.G:G;3Z7=SW,VF:GIMW$
MMU<V<UC/+^E%_:6]_8WMC=PQW%K>6ES:7-O,BR0SV]Q"\,T,L;AD>.6-V1T8
M%65BK @D5_*Q_P &_$46F?M(?M=Z-9KY%A;^%='2&VC)$,<>G^-K^WME"YY\
MF*X=(R1D*S\C<<_.U,=E?'_ ?&F9XKA?A[(LYX/>48[+L;PY@%ED:V"S#&_4
MZN7XVA";CB8TXZPK5+U+J%1<E1357Z&G@<TX"X[X,RS"\3\09YD_%ZS? YC@
MN(L>\SE2QN P7UREF&#K3A&6'G.6DZ-/EI\KG3:J4W!TONW_ (*J?\%2O%G[
M)OB7P[^SY^SYH.G^(?CMXLTO3=8U#6-3TV;7;3P?8:W>RV6@Z9I/A^+":YXP
MUU[>2>VM[P7-GIUG-ITLFEZK+JT,=I^?^LZS_P %^?@QX0E_:.\6:YX@UOPW
MH]C)XG\4^"-27X6>(9=-\/V]O+>7DNN?#[1K6/4K"PM+5&GU.+08K76-+MT>
M6[:Q6"YDAL_M!6MGXA_X.#/AC8:G;QW5K9^-/@[/'#,!)$+C1?AEHVN6$H1@
M5S!J-G;W*#'$L8/J:_JTN[2VO[6YL;V"*ZL[RWFM+NVF020W%M<1M#/!-&P*
MO%+$[QR(P(9&*D8-=689MDOAUD7 F#PG!_#>=UN(^',+Q#Q%CL_P"S#&8N..
MQ,Z;P.#JSG; 4Z=&,U2J4$G"2I2Y)R]M4ERY?E6<^(>>\=8O%\7\1Y)1X=XB
MQ/#W#V"R''/ 83"2P6&C46.QE*$7]?J5*TH.K3K2:J1=5<T(JC3C_*CXJ_X+
M7?M7?M2:?\,/@C^QI\'I/#/Q[\7Z;/!XWU6SL=-\4W":[;I??:$^'UGK\ESH
MNB>'XK"V77=1UWQK'>-I4<DEC+);0:5)KNI\U\1_V@O^"UW_  3_ '\/?%;X
M_P"K?\+#^&.HZI966LVVO1>!/&GA&.\NY5E&BZQJ?@R&TU_PI>7D,$]OIUY;
M:EI^G27#>5;27LNVV=?^"#G@[1M)_;@_::ABLH9)?!OP]\6Z%HUS+&K365J?
MB9X9L)1"Q'[MY[>QBBD9 "T>],A693^\G_!4.PL]1_8 _:CAO;:&ZB@^&MQJ
M,4<\:R*EYI6KZ3J5C<*&!VRVMW:PW$,@YCDC5@>*^DS[,>%>$N.<IX#RW@3A
MC%9!F4\D_M.OF>#J8[-Z[XGJ4YIX;,:]:5;!PRZCCJ$<+2IRM:BX.<$H57\Y
MD67\4\6<#YMQWF7'7$^%S[+:>=?V90RS&4\#E%#_ %9IS@UB<OH48T<9/,*N
M!KRQ52I&]ZW.H3O.DO9_V2_VEO!O[7/P&\#?'3P3!-IUCXIM+B#5] NIEN+W
MPQXGTFX>PU_P_=3K'"+C[#?1.]E>B" :EI<]AJ2V\"7BQ)^4O_!*G]N7]H[]
MJ7]I7]IKP)\8_%VG:WX4\ :5=7_A31[#PSH&BII$Y\;'28TBO-,T^VU&ZMX=
M/)MHTU*\OI"H2225Y@TKS_\ !O9>SS_L:^/K.25WAL?CUXD\B-F)6(7/@GP"
M\@0'[H=D#$# +9;&22?CW_@A(0/VQ_VS4/#'P[=$ ]<)\2%#<>Q=0?K7R]7A
M3)LIPWCQ@88*AB5PW'*H9)B<52A7Q>7TJ^<T)?[/7J)U*=3ZOB8X:I6C:I5I
M4H^T=YSO]12XJSC-L1X%8Z>-KX9\1RS6>=8;"U)4,+F%6ADU>/\ M%"#Y*E/
MZQAGB:=&5Z=*I5ER*T8<O]4E?@K\"?V[_P!H[QQ_P5K^)_[)WB/Q5I%W\%_#
M6O?%73](T"+PKX?M;^WM?"^B7^H:*C:[;V,>LRRV\UM"999[V;[2HE65")1Y
M?[U5_*E^S "?^#@#XUD'A?%/QQ)QR,?\(EJJX/IAB/Q '>OEO#C+<OS#+/$J
MICL#A<94R_@+'8[ 5,30A6G@L93QE"$,5A93UHXB,9.,:L/>46TM&?4>(N8Y
MA@,R\-Z>!QN*P=/,./,#@L?##5IT8XW!U,'7G/"XF,-*V'E**E*E/W7))O5(
M^E/^"FG_  4O^.W[%_[:7PE\&>&]4M+OX)R^"O GC;Q[X+A\-^'+K7/$5G/X
MT\46?B?3M/\ $6JV<U[IESJ^AZ/!I]C/!<P1Z9='[:%E8NC<!^S%\:/^"OG[
M8_QG^&?Q_6W_ .%4?LDS?$#PWK&HZ %\'^%O#6J_"^T\3PR^(X=-?7[.?QYX
MR67P[%>6S:_@:;JMPIETB?3%8QV7S9_P6K\'VOQ"_P""E_[.'@.]61[+QKX)
M^#OA.[6)S'+]F\1_%;Q=HT[1NI#(Z1WK.K(=X*_+\V*_H"_X*&WVM?"W_@G)
M^U_=?"FT.C:GX'_9/^+L'@ZVT6'R#H-IHOPVUBTM7TB&W7_1SH6EPM/IZ0)^
MX-G"(U^117V^/Q&0\/<&^&]+ <*\.XGB3C+(9X'$YOFF!CB883"XC,J^73QL
M</SPI5<UJ5\PA[/,*UZN'H8&C"F[J"/DLCRW/^+N/N.L-C.*^(,%P]PWQ3@I
M83+,NQTL-]8Q<\/@,12PM7$<DJM/*:-'#RE5P%%JEB*V+K.:7-*1^ ?Q_P#^
M"H__  4)_P""DG[2WCG]D;_@C?I=EX4^&'PUOIM&^)/[6&J6VG1VUU+!>36=
MQK-EXIU[3]7T?P9X.O;JQOK7PHFBZ+K7Q$\96]O-KFAI8V23VEKJQ_\ !/W_
M (+S? .^T;Q9X-_X*X^"_B9\69P-0T_X*?%CQKXJU3PYXWDMV$EWH.@V?Q+T
MG7M*U+[24:UCF_X1_P -"-6.-4T@@31?7/\ P3S\-V_["'_!%_\ 9_UKX >"
MK+Q3\?/VC_#O@GQ-X>M8(+:XN?'/QT_:!>WF\/W6MSR26L-UI7@/PS-:^;'=
MW-M90>&_!,RW%Q:K)>7E?.6C?\$/?VS?BE\3=&^,G[1/[4'A)?&-[X@TWQ'X
MCU;3]2\7>,O&6GO!?Q:@T.EW]SI/A[2;:]L"&CTN'3KR+1]*EC@33@+*WABI
M9;/AW#_VEAGF7"'"/#658C&Y1@IYUPYA^)N(.+L?EBE1Q^,Q$*M*IB*."EBH
M>RD\/5P4*<J]+"X)NO2J5*/Z;Q5QAG.3X_#Y1PMP?B^*<6O85<QJ0JX?!X'+
M\+7K.G3EBL=BFE+&8F%/$5Z.%I1DJ6&H_6,0XTYTH5/UA_X)L?M\^+_VL-&^
M)/PB_:-^%T_[/_[:'[.&H:5H/Q\^$-YOCT^>VUF"27PW\2? TEQ<7;7G@KQ9
M';S/ 8;_ %:#3[E8C;ZOJNCZGH6K:E^H9( ))P!R2>@'J:_)KXJV_P +9O\
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M%_ L>KG4=(L9X(9?%O'_ ,3?^"Z/[$>GP?&+XK:SJGC_ .'-BT-SXIAU3_A
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MP+33%;4M*^$7PXGULVVM>,]>U/5FCOO$VN/;VL6IWMII<DZ6>@>&4U:?TO\
M8QM/B#XZ_8J_X*#?M:_$K3)-"U3]K2T^.'Q!\-:)*DP^Q?#_ $/X<>)-)\,&
M)ITCEFLTEN=6TW3+EHU%]I&EZ?J,>Z*\C8\UX5_X)<?!34_BI;^.OVY/VY;C
M]I_Q3X5OFC'@?Q=XYL?#FDVMU93Q22Z7K\>M^.?$/B)=/66WC:]\/Z;-X;@D
MEC9;\W44L\+_ ++:_K'P#\9_"GQ?X"_X3SX>VGPUOO"%U\-];_X1KQCX7T[3
M/#WA_P 4:)>>&[72;2[LKQM.T&233&N+70X2D:)]F"VENZ6YC'?GV=X'#QK?
M5L9F/%&<Y_FN0XOB+B&GD>897E.%RG)LQPF.P.1</8'%8:&)J4IUJ-.K4Q%2
M-"$X87"87"TY>TJU9_+P_M_BK-JN<9]2R[A_"99EF=X7(LAEG.6X_,*V99IE
M>)RS$9KG-? XB6#PE/"X2;PF$P.'==T%7Q>*Q512C&"_$/\ X-SR/^%+?M(C
M(S_PMCPX<9&=I\*N%/T)#8]P<=Z_HQK\Z?V'/V=_V3/V+= \3?#[X+_&K3O&
M-Y\2O%=EJ]X?$WQ&\"ZSKE]J<-J=.TO2M'L/#L.D1,$2658H8K&>^NIIB'ED
M5(8X_M6\^+7PJT_49]'O_B9\/K'5[:Z>RN=+O/&?ARVU&WO(W,3VD]C-J27,
M5TD@,;V\D2RJX*% PQ7RWB+F%/B7C?B'.LJPN93P.8XJGB<-]9RW&8;$.C#"
M8/#RJ5,-.A4J4X^UH5(IR;6BO)2?*O4\.\OJ<-\$\/Y+FF)RZ.-R[#5,-B?J
MV8X/$X=5IXO&8B-.&(A6A3J2]C7IR:BD[MVBXKF?\R__  0D_P"3ROVR.!_R
M+VL\XY_Y*=:< ^A[CO@>E%?M;^R=_P $[O@?^R)\3/BE\6OAAK_CW6-9^+D5
MQ%J-KXHUC1M1T;2M.OM;'B)[?15TS0]+N94:[6W6*ZU*\U&<6T(592TTTDA5
M>)O$>6<5<65\XRB6(G@IY7D>$B\5AY86M[; 970PF)BZ,ZE22C&O"<82YK34
M>=)1:1/AIP[F7"W"E#)\VCAXXVGF>=XN2PN(CB:7L<?FE?%8:2JQA3BY2H3A
M*<>6\')0;DTV??E%%%?GY]\%%%% !1110 4444 %%%% !1110 5^:'_!6X _
ML7^( 0"#\7/V>5(/=7^-_@1&'T9692.ZD@\&OTOKXZ_;O^ /CG]IC]G'Q#\*
M?AQJ?A?2?&%YXL^&_BC2;OQE-JEOX=+^!?'OA_QA+:ZA-HUCJ.HQI>1:*]JC
M6]I(P>5<M&,NOT/"6*P^"XHX?QF+K4\-A<-F^!K8C$56XTJ%&%2?/5J2C&<E
M""DG)J$VHW?*[6/G^+,+B,;PQG^$PE&>)Q6)RG&T</AZ24JE:K.G3Y*5.,I0
MBYS<6HIS@G*RYE>Y]BU_+WJG@#3_ (K?\$V_V??A7JMU-8Z7\3/^"H-Q\.[^
M]MFV3V5EXR^-GQ4\,S7,+88J;:#42V%&3&AC& >/VN\%ZE_P41D\6^&X_B%X
M4_8ZM? KZS8+XMN?!_C#XR7GBJ#P^9T&IR^'K76?"=II5QJZ6WF-8PZA<P6D
MDX19Y4C)8?-GAS]@GXJZ/^SW\ _A+/XH\"/KWPJ_;NT7]J+7;Z*ZUQ]*O_ ^
MF_%GQ3X\FT72Y'T6*Z;Q/+I6N6MO'!=6L&F+?1SQ-J30JES)]APIC,+PPZDL
M1G>4K$_VUD.986ME^/\ KL:7]G8+C2#JRG3P5*-.=#%XS+&H2C)OZQ1DE*,J
MBA\AQ5A,5Q-&$</DN:O#_P!C9[EN)HYA@/J4JO\ :&.X,FJ485<94E4IU\)@
M\S3G&44OJ]:+<9*#G2/[4OQ!_P"'=:0F6,_M5OXA'[#QT[S?]+'[3)\2GX/G
M5,[AF06@/Q8&!Y9T;%QL%N3C\[K'P%8_"G_@F#^U%\+M+NYK[3OAM_P4DB^'
M]C?7!W7%[9^$/CA\'/#<-U,VU=S7,.GAS\JX1Q'M 7%?K7_PP_K7_#<P_:%_
MX2O3/^%&?;C\8C\)_P#21<?\-0?\(,OPE_X6%]D%A_9QL?\ A7RB[,YU/[9_
MPE6;T6&2UV?+_%'[ _Q6UK]FG]H_X,VWBGP(OB/XP_MLZU^TIX=U"6YUU-'T
M[P9J7Q:\&>/8-'UB1=&EO%\1Q:5X<O+>6&TM+C3FOI;>)-0$#27,7OY5Q#PU
ME\J5+"YAA<-A\RXBX7XLQ\.6M3A@\3/,\Q=?*U^X;]GP[A*F,<^3FI*&:X5T
M95I0FJ?@YKP_Q+F$:M7%8#%8G$9=P[Q1PG@)N5*I/&8>.69?&AFC_?I*IQ!B
MZ>#47-1JN>5XI58T8S@ZG*_\%3OV:?V>;+X)2?$FT^"/PMM_B!XG_:%^!Z^(
M_&D/@CP_%XGUQ?%7Q4T&R\3+JNMQV*ZC?+K]G>7=KJXN;B0:A!=3QW(D$C9@
M_P""D/P*^ ?P2_9H\.)\.O@/X)T#0_$O[3O[.Q\;^#_AM\/]!LKOXAZ;IGBG
M4$7P[<:)IEK8P^)+J\L]0U/3-.TN\<QW#ZI/:!HTNY2?N?\ ;4^ ?BO]I#X-
MV'P[\&ZGH6DZQ:?%+X4>.'NO$4U]!I[:9X$\<Z1XFU2W633['4;@WMQ9:?+%
M91FW6&6X*1S3VT;&9,S]N+X$_$?]H'X2>&/#/PIO?!MEXU\(?&'X9?%+3!X]
MO-9L/#-[_P *_P!;;6CIU]=:#INJZG&MY*L,9^SVFYHO-430.4D'A<.\4.C_
M *AT<=GV)C1R_B#.JV94L1F>9*CA\'*E@H99+$_OZT:="$J<EA90I5W@^1U:
M%&A*E"_N<0<,*M_KU5P618:5;'Y!DM'+:N'RS+I5L1C(U,9+,HX9>QHRJ5YQ
MJ1>*C.K06,YU2KUJ\:L[?-_P8L/V2=3^*W@FV\*?\$R?BC\(_$T>NQZAH/Q,
M\4_LC^$_ VA>#M6TF&?5;'6KSQ;:7\]SH3Q7%DD=A?0Q-*NHRV<<>QY Z^:_
ML2?LP_LY_&J^_;:\0_%OX'?"WXD>((_V[OVB=#CU[QGX*T+Q!K,6CPWNA7$&
MF0:EJ5G<7=O9V]Q?7L\$,$L2QSW=Q*N))&:OLWP9J7_!1&3Q;X;C^(/A3]CJ
MU\"OK6GKXMN?"'C'XR7GBJW\/&X0:I+X?M=8\)V>E7&KI:>8;&+4+F"SDN B
MSR)&68?/?PR^!?[?/[/WB/X_V7PBC_9)U[P;\8/VA_B9\;=)U7XC:_\ %V'Q
M)H\7C^[L##INHZ3X:\.QZ=<_V;;:; [Q6NJ0M-/+<1"]V"*47_:-5X7/*&'X
MBP66X[%X3(E@Z_\ KUG.9J4,'GN,Q.-I+-L70IXC"S]C5HUG@8)4JT(JLG.H
MG!9_V?16)R2O7X=QN8X'"XS/'C*"X&R?+)*>+R/"8;!57E6%K5,/BH^VIUJ*
MQT[U:,Y.B^2FU-[_ .Q?:R?!K]J+]L3]D?PQ>ZA/\%OAC:_!GXF?"3P_?ZG?
MZO\ \*VM/BMH&M7'B?P)IMYJ5Q=W</AN'6='&I^&]*,_E:9:7%Q'&KR333RE
M?0?[*_[->N?!&3XI_$'XF>.8/B?\>OCSXHT[Q9\5_'%CHX\/Z%MT#3/[%\(>
M#/"6C-/=7%CX1\%Z.\UAH_V^ZN-1NOM%Q<W3QAX;:W*^+XJQF&Q^=5L1AL1'
M&6PF5T,5F$(3IPS+,<+EF#PV99E&-6G1JR6-QM*K55:M2I5L5R/&5J<:N+FG
M]IPM@\3@<FHX?$T)8-O%YG7PV G.%2>6Y?BLRQF)R[+I2IU*U*+P6"JTJ7L:
M-6K1PO.L'1J2I82#7UQ1117SI]"%%%% !1110 4444 %%%% !1110 4444 %
6%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
